These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19770002)

  • 1. Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.
    Atack JR
    Pharmacol Ther; 2010 Jan; 125(1):11-26. PubMed ID: 19770002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
    Atack JR; Maubach KA; Wafford KA; O'Connor D; Rodrigues AD; Evans DC; Tattersall FD; Chambers MS; MacLeod AM; Eng WS; Ryan C; Hostetler E; Sanabria SM; Gibson RE; Krause S; Burns HD; Hargreaves RJ; Agrawal NG; McKernan RM; Murphy MG; Gingrich K; Dawson GR; Musson DG; Petty KJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):470-84. PubMed ID: 19704033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
    Atack JR; Bayley PJ; Seabrook GR; Wafford KA; McKernan RM; Dawson GR
    Neuropharmacology; 2006 Nov; 51(6):1023-9. PubMed ID: 17046030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition.
    Chambers MS; Atack JR; Broughton HB; Collinson N; Cook S; Dawson GR; Hobbs SC; Marshall G; Maubach KA; Pillai GV; Reeve AJ; MacLeod AM
    J Med Chem; 2003 May; 46(11):2227-40. PubMed ID: 12747794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging.
    Eng W; Atack JR; Bergstrom M; Sanabria S; Appel L; Dawson GR; Sciberras D; Hargreaves RJ; Langstrom B; Burns HD
    Neuropharmacology; 2010 Dec; 59(7-8):635-9. PubMed ID: 20696179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.
    Dawson GR; Maubach KA; Collinson N; Cobain M; Everitt BJ; MacLeod AM; Choudhury HI; McDonald LM; Pillai G; Rycroft W; Smith AJ; Sternfeld F; Tattersall FD; Wafford KA; Reynolds DS; Seabrook GR; Atack JR
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1335-45. PubMed ID: 16326923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.
    Atack JR
    CNS Neurosci Ther; 2008; 14(1):25-35. PubMed ID: 18482097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
    Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC
    J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6,2'-Dihydroxyflavone, a subtype-selective partial inverse agonist of GABAA receptor benzodiazepine site.
    Wang F; Xu Z; Yuen CT; Chow CY; Lui YL; Tsang SY; Xue H
    Neuropharmacology; 2007 Sep; 53(4):574-82. PubMed ID: 17681556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
    Atack JR
    Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze.
    Collinson N; Atack JR; Laughton P; Dawson GR; Stephens DN
    Psychopharmacology (Berl); 2006 Nov; 188(4):619-28. PubMed ID: 16633803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GABA-based therapeutic approaches: GABAA receptor subtype functions.
    Rudolph U; Möhler H
    Curr Opin Pharmacol; 2006 Feb; 6(1):18-23. PubMed ID: 16376150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.
    Löscher W; Potschka H; Rieck S; Tipold A; Rundfeldt C
    Epilepsia; 2004 Oct; 45(10):1228-39. PubMed ID: 15461677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.
    de Haas SL; Franson KL; Schmitt JA; Cohen AF; Fau JB; Dubruc C; van Gerven JM
    J Psychopharmacol; 2009 Aug; 23(6):625-32. PubMed ID: 18635696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γ-Aminobutyric acid type A (GABA(A)) receptor subtype inverse agonists as therapeutic agents in cognition.
    Gabriella G; Giovanna C
    Methods Enzymol; 2010; 485():197-211. PubMed ID: 21050918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.
    Street LJ; Sternfeld F; Jelley RA; Reeve AJ; Carling RW; Moore KW; McKernan RM; Sohal B; Cook S; Pike A; Dawson GR; Bromidge FA; Wafford KA; Seabrook GR; Thompson SA; Marshall G; Pillai GV; Castro JL; Atack JR; MacLeod AM
    J Med Chem; 2004 Jul; 47(14):3642-57. PubMed ID: 15214791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term memory impairment after isoflurane in mice is prevented by the α5 γ-aminobutyric acid type A receptor inverse agonist L-655,708.
    Saab BJ; Maclean AJ; Kanisek M; Zurek AA; Martin LJ; Roder JC; Orser BA
    Anesthesiology; 2010 Nov; 113(5):1061-71. PubMed ID: 20966663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated.
    Atack JR; Bayley PJ; Fletcher SR; McKernan RM; Wafford KA; Dawson GR
    Eur J Pharmacol; 2006 Oct; 548(1-3):77-82. PubMed ID: 16962577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.
    Ballard TM; Knoflach F; Prinssen E; Borroni E; Vivian JA; Basile J; Gasser R; Moreau JL; Wettstein JG; Buettelmann B; Knust H; Thomas AW; Trube G; Hernandez MC
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):207-23. PubMed ID: 18936916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo labelling of alpha5 subunit-containing GABA(A) receptors using the selective radioligand [(3)H]L-655,708.
    Atack JR; Alder L; Cook SM; Smith AJ; McKernan RM
    Neuropharmacology; 2005 Aug; 49(2):220-9. PubMed ID: 15996568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.